To ascertain if there were significant differences in SFRP5, WNT5A and PPARγ mRNA expression in adipose tissue (SAT and VAT) according to NAFLD presence, we first classified the MO cohort (the only one with liver biopsy for diagnosis) into NL and NAFLD. This evidence concerns the gene SFRP5 and metabolic dysfunction-associated steatotic liver disease.